-
Pegvisomant
- indication:Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
- pharmacologypharmacology:
- mechanism: Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
- toxicity:
- absorprion:
- halflife: ~6 days
- roouteelimination:
- volumedistribution: * 7 L
- clearance: * 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]